Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Kohen

Allergy & Immunology Daytona Beach, FL Medical Doctor

NPI 1013909951 CMS profile 1145

709 N Clyde Morris Blvd, Daytona Beach, FL 32114

Open in the dashboard

General payments

$26,230

1,210 records reported · program years 2019–2025

Research payments

$2,282

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,540,302 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Kohen of Daytona Beach, FL is reported in the CMS Open Payments database as having received $26,230 across 1,210 general payments and $2,282 in research payments paid to them. Separately, studies naming them as principal investigator received $3,540,302 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,588 140
2024 General $3,414 151
2023 General $4,213 179
2022 General $4,370 189
2021 General $3,731 193
2020 General $3,284 168
2020 Research $2,282 2
2019 General $3,630 190

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Kohen
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Michael Kohen were reported at $3,588. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Michael Kohen Allergy & Immunology median Middle half National median
2019 $3,630 $594 $163–$1,512 $163
2020 $3,284 $426 $106–$1,233 $114
2021 $3,731 $638 $157–$1,708 $132
2022 $4,370 $790 $205–$1,961 $149
2023 $4,213 $852 $220–$2,147 $160
2024 $3,414 $865 $203–$2,267 $164
2025 $3,588 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $3,402 159 payments
  2. AbbVie, Inc. $3,177 164 payments
  3. UCB, Inc. $2,568 102 payments
  4. Pfizer Inc. $1,981 124 payments
  5. Janssen Biotech, Inc. $1,825 70 payments
  6. Lilly USA, LLC $1,331 66 payments
  7. Novartis Pharmaceuticals Corporation $1,175 56 payments
  8. AstraZeneca Pharmaceuticals LP $1,118 54 payments
  9. GlaxoSmithKline, LLC. $1,075 61 payments
  10. Horizon Therapeutics plc $1,033 64 payments
  11. Other $7,545 290 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $25,618 1,200 payments
  2. Education $372 9 payments
  3. Grant $240 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $2,110 105 payments
  2. Cimzia $1,928 77 payments
  3. XELJANZ $1,596 100 payments
  4. TREMFYA $1,390 45 payments
  5. TALTZ $1,329 64 payments
  6. SIMPONI ARIA $934 41 payments
  7. BENLYSTA $904 50 payments
  8. KRYSTEXXA $854 51 payments
  9. EVENITY $841 42 payments
  10. Prolia $839 45 payments
  11. Other $17,975 841 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,282 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

4,830

Median for Allergy/ Immunology: 449

Drug cost

$1,918,978

Median for Allergy/ Immunology: $169,700

Branded share of claims

26.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xeljanz Xr Tofacitinib Citrate Brand 61 $382,375
Cimzia (2 Pack) Certolizumab Pegol Brand 52 $361,730
Enbrel Mini Etanercept Brand 32 $239,715
Rinvoq Upadacitinib Brand 34 $239,042
Enbrel Etanercept Brand 22 $162,886
Enbrel Sureclick Etanercept Brand 14 $104,990
Humira(Cf) Pen Adalimumab Brand 14 $95,626
Olumiant Baricitinib Brand 23 $62,846
Breo Ellipta Fluticasone/Vilanterol Brand 51 $36,799
Prolia Denosumab Brand 21 $35,718

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$987,436

Of which drugs: $687,479

Medicare patients

739

Average age 75

Services billed

200,024

548 women, 191 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 32%
Chronic kidney disease 30%
Osteoporosis 29%
COPD 25%
Diabetes 24%
Depression 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 46 181,600 $657,719
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 56 475 $322

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XELJANZ
$334 61 —
RINVOQ
$320 34 —
TREMFYA
$281 — —
COSENTYX
$254 — —
KRYSTEXXA
$254 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

1,212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record